Abstract: Provided an electrophotographic electro-conductive member that can stably suppress an occurrence of fogging in an electrophotographic image. The member comprises a support having an electro-conductive outer surface, and an electro-conductive layer on the outer surface of the support, the electro-conductive layer having a matrix including a cross-linked product of a first rubber, and domains dispersed in the matrix, the domains each includes a cross-linked product of a second rubber and an electro-conductive particle, at least some of the domains is exposed to the outer surface of the electro-conductive member to constitute protrusions on an outer surface of the member, the outer surface of the electro-conductive member is constituted by the matrix and the domains exposed to the outer surface of the electrophotographic electro-conductive member, the electrophotographic electro-conductive member has an impedance of 1.0×103? or more and 1.0×108? or less, and some of the domains satisfy two specific requirements.

Abstract: [Problem] To provide a terminal registration system and a terminal registration method for improving user convenience in registration of a new terminal to a plurality of service sites. [Solution] The registered terminal 1 includes an Authenticator 10 including service site list information 110 that associates private keys and URLs for access to service sites with each other. A Registration Manager 100 acquires the service site list information 110 from the Authenticator 10 of the registered terminal 1. Then, the Registration Manager 100 performs FIDO authentication for a registration target service site using a private key of the registered terminal 1, on the basis of the acquired service site list information 110, and performs Registration of a newly generated cryptographic key at the new terminal 2.

Abstract: [Problem] To provide a terminal registration system and a terminal registration method for improving user convenience in registration of a new terminal to a plurality of service sites. [Solution] The registered terminal 1 includes an Authenticator 10 including service site list information 110 that associates private keys and URLs for access to service sites with each other. A Registration Manager 100 acquires the service site list information 110 from the Authenticator 10 of the registered terminal 1. Then, the Registration Manager 100 performs FIDO authentication for a registration target service site using a private key of the registered terminal 1, on the basis of the acquired service site list information 110, and performs Registration of a newly generated cryptographic key at the new terminal 2.

Abstract: To provide a terminal registration system and a terminal registration method for improving user convenience in registration of a new terminal to a plurality of service sites. The registered terminal 1 includes an Authenticator 10 including service site list information 110 that associates private keys and URLs for access to service sites with each other. A Registration Manager 100 acquires the service site list information 110 from the Authenticator 10 of the registered terminal 1. Then, the Registration Manager 100 performs FIDO authentication for a registration target service site using a private key of the registered terminal 1, on the basis of the acquired service site list information 110, and performs Registration of a newly generated cryptographic key at the new terminal 2.

Abstract: [Problem] To provide a terminal registration system and a terminal registration method for improving user convenience in registration of a new terminal to a plurality of service sites. [Solution] The registered terminal 1 includes an Authenticator 10 including service site list information 110 that associates private keys and URLs for access to service sites with each other. A Registration Manager 100 acquires the service site list information 110 from the Authenticator 10 of the registered terminal 1. Then, the Registration Manager 100 performs FIDO authentication for a registration target service site using a private key of the registered terminal 1, on the basis of the acquired service site list information 110, and performs Registration of a newly generated cryptographic key at the new terminal 2.

Abstract: The present invention provides an agent that suppresses a decrease in arterial oxygen saturation or increases decreased arterial oxygen saturation, and that can be ingested by a relatively simple method and has excellent immediate effectivity and persistence. The agent of the invention comprises orotic acid or a salt thereof as an active ingredient, which is absorbed into the body via oral mucosa. When the agent is absorbed in the body via oral mucosa it suppresses a decrease in arterial oxygen saturation or increases decreased arterial oxygen saturation. The agent is effective for improvement or prevention of a symptom or disease related to a decrease in arterial oxygen saturation, such as exercise, alcohol drinking, a decrease in oxygen concentration in air, reduced cardiopulmonary function, and respiratory arrest, and a symptom or disease caused by hypoxia, in particular, for prevention of an increase in uric acid level.

Abstract: The present invention addresses the problem of providing an agent for decreasing heart rate having fewer side effects, or a novel agent for suppressing an increase in heart rate during exercise. The heart rate can be decreased, in particular, palpitation, shortness of breath or fatigue associated with an increased heart rate can be prevented or ameliorated, and the increase in heart rate during exercise can be suppressed by ingesting a preparation containing orotic acid or a salt thereof as an active ingredient.

Abstract: [Problem] To provide a terminal registration system and a terminal registration method for improving user convenience in registration of a new terminal to a plurality of service sites. [Solution] The registered terminal 1 includes an Authenticator 10 including service site list information 110 that associates private keys and URLs for access to service sites with each other. A Registration Manager 100 acquires the service site list information 110 from the Authenticator 10 of the registered terminal 1. Then, the Registration Manager 100 performs FIDO authentication for a registration target service site using a private key of the registered terminal 1, on the basis of the acquired service site list information 110, and performs Registration of a newly generated cryptographic key at the new terminal 2.

Abstract: The present invention provides an agent that suppresses a decrease in arterial oxygen saturation or increases decreased arterial oxygen saturation, and that can be ingested by a relatively simple method and has excellent immediate effectivity and persistence. The agent of the invention comprises orotic acid or a salt thereof as an active ingredient, which is absorbed into the body via oral mucosa. When the agent is absorbed in the body via oral mucosa it suppresses a decrease in arterial oxygen saturation or increases decreased arterial oxygen saturation. The agent is effective for improvement or prevention of a symptom or disease related to a decrease in arterial oxygen saturation, such as exercise, alcohol drinking, a decrease in oxygen concentration in air, reduced cardiopulmonary function, and respiratory arrest, and a symptom or disease caused by hypoxia, in particular, for prevention of an increase in uric acid level.

Abstract: A hydrogen-absorbing alloy, which is used as a negative electrode material of nickel-metal hydride secondary batteries for hybrid electric vehicles, and particularly for batteries to drive electric motors of hybrid electric vehicles, is an AB5-type alloy having a CaCu5-type crystal structure and the general formula RNiaCobAlcMnd (R: mixture of rare earth metals), wherein 4.15?a?4.4, 0.15?b?0.35, 1?c/d?1.7, 5.25?a+b+c+d?5.45.

Abstract: A hydrogen-absorbing alloy, which is used as a negative electrode material of nickel-metal hydride secondary batteries for hybrid electric vehicles, and particularly for batteries to drive electric motors of hybrid electric vehicles, is an AB5-type alloy having a CaCu5-type crystal structure and the general formula R NiaCobAlcMnd (R: mixture of rare earth metals), wherein 4.15?a?4.4, 0.15?b?0.35, 1?c/d?1.7, 5.25?a+b+c+d?5.45.

Abstract: A composition and a method effective in preventing or treating stomatitis are presented. The composition contains glutathione or a pharmaceutically acceptable salt thereof and/or orotic acid or a derivative thereof or a pharmaceutically acceptable salt thereof is provided.

Abstract: The invention provides a composition for preventing or treating infectious diseases of a virus belonging to the Coronavirus family or Flavivirus family, the composition containing one or more substances selected from reduced glutathione or oxidized glutathione or pharmaceutically acceptable salts thereof and catechin, and a composition for preventing or treating infectious diseases of a virus belonging to the Coronavirus family or Flavivirus family, the composition containing reduced glutathione or oxidized glutathione or pharmaceutically acceptable salts thereof and catechin.

Abstract: A composition and a method effective in preventing or treating stomatitis are presented. The composition contains glutathione or a pharmaceutically acceptable salt thereof and/or orotic acid or a derivative thereof or a pharmaceutically acceptable salt thereof is provided.

Abstract: A temperature-sensitive plasmid which is capable of autonomous replication in Escherichia coli K-12 at 10–30° C., but, at a temperature of 33° C. or more, is incapable of autonomous replication in Escherichia coli K-12 or is distributed unhomogeneously upon the cell division of Escherichia coli K-12, thereby not to be stably carried within cells of Escherichia coli K-12 under said temperature, and which is incapable of autonomous replication in a microorganism belonging to the genus Escherichia other than Escherichia coli K-12 or is distributed unhomogeneously upon cell division of said microorganism at any temperature, thereby not to be stably carried within cells of said microorganism.

Abstract: The invention provides a composition for preventing or treating infectious diseases of a virus belonging to the Coronavirus family or Flavivirus family, the composition containing one or more substances selected from reduced glutathione or oxidized glutathione or pharmaceutically acceptable salts thereof and catechin, and a composition for preventing or treating infectious diseases of a virus belonging to the Coronavirus family or Flavivirus family, the composition containing reduced glutathione or oxidized glutathione or pharmaceutically acceptable salts thereof and catechin.

Abstract: The object of the present invention is to provide antiinflammatory agents for airway, foods and drinks, animal feeds, food additives, feed additives and a method for preventing or treating airway inflammations. The object is achieved by providing antiinflammatory agents for airway, foods and drinks, animal feeds, food additives and feed additives, each comprising, as the active ingredient thereof, orotic acid or its derivative or a salt thereof; and a method for preventing or treating airway inflammations which comprises administering orotic acid or its derivative or a salt thereof.

Abstract: The present invention relates to a method of improving the hatchability of eggs and a composition used for the method. The present invention provides the method comprising administrating an amino acid solution into hatching eggs and a composition for improving the hatchability of eggs which contains an amino acid as an effective ingredient.

Abstract: Administration of one or more of glutathione, its disulfide dimer, ascorbate-2-phosphate, or N-acetyl-L-cysteine, with or without antioxidants, is suitable for the treatment of influenza virus infection, as well as prophylactic prevention of influenza virus infection.

Abstract: Administration of one or more of glutathione, its disulfide dimer, ascorbate-2-phosphate, or N-acetyl-L-cysteine, with or without antioxidants, is suitable for the treatment of influenza virus infection, as well as prophylactic prevention of influenza virus infection.